Skip to main content

Table 1 Characteristics of the subjects in this study

From: Is greater generic competition also linked to lower drug prices in South Korea?

Variables All Duopoly
(2)
Low-competition
(3–25)
Medium-
Competition
(26–75)
High-competition
(76-)
p-value
N = 986 305 554 88 39
Price variance  
 Mean 0.1167 0.0683 0.1160 0.2268 0.2566 <  0.0001
 Median 0.0714 0.0130 0.0774 0.2004 0.2286
 SD 0.1416 0.1000 0.1366 0.1782 0.1693
ATC  
 1 (J/L) 168 58 97 11 2 <  0.0001
 2 (A/B/C) 302 100 140 41 21
 3 (M/N) 239 57 148 24 10
 4 (Others) 277 90 169 12 6
Route  
 Oral 635 156 354 86 39 <  0.0001
 Injection 206 103 101 2
 Others 145 46 99
Year  
 Mean 2007 2008 2007 2006 2005 0.0001
 Median 2006 2007 2006 2006 2005
 SD 5.3662 5.2816 5.5529 4.5851 3.8231
Types  
 Biologics 50 28 9 9 4 <  0.0001
 Chemicals 936 277 545 79 35
New drug application
 Yes 154 34 96 13 11 0.0142
 No 832 271 458 75 28
Manufacturers
 Domestic 623 187 372 49 15 0.0008
 Overseas 363 118 182 39 24
Price
 I (<  103 KRW) 502 120 283 67 32 <  0.0001
 II (103 ≤ <  104) 269 86 159 17 7
 III (104 ≤ <  105) 154 67 83 4
 IV (105 ≤ <  106) 55 26 29
 V (106≤) 6 6